Treatment Persistence and Switching Patterns of Adalimumab Biosimilar ABP 501 in European Patients with Rheumatologic Diseases

Abstract Introduction ABP 501 was an adalimumab (ADA) biosimilar approved for treating immune-mediated inflammatory diseases (IMIDs) including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). In this retrospective study, we aimed to examine the treatment pattern...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Ran Jin, Silvia Kruppert, Florian Scholz, Isabelle Bardoulat, Khalil Karzazi, Francois Morand, Greg Kricorian, David Collier, Jonathan Kay
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Adis, Springer Healthcare 2024-03-01
Saila:	Rheumatology and Therapy
Gaiak:	ABP 501 Adalimumab Arthritis, Psoriatic Arthritis, Rheumatoid Biosimilar pharmaceuticals Medication adherence
Sarrera elektronikoa:	https://doi.org/10.1007/s40744-024-00647-4
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!